Status: Recruiting
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study. In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen and escalating doses of oral ATG-010 weekly in a 3+3 design. Then a phase 2 expansion at the recommended dose level based on phase 1b trial will be conducted to evaluate the efficacy, safety and tolerability.
Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Tong Chen, MDUpdated: Sep 16, 2025Locations: 5
Eligibility criteria
Participants must be able to understand and be willing to sign a written informe... [+14]
Patients with SCNSL actively receiving treatment for extra-CNS disease are exclu... [+15]